Market Closed -
Japan Exchange
02:00:00 2024-05-16 am EDT
5-day change
1st Jan Change
2,661
JPY
-2.81%
-1.84%
+13.14%
Mar. 25
Towa Pharmaceutical Completes Payment for Director Stock Compensation
MT
Mar. 07
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors
CI
Sales 2024
228B
1.47B
Sales 2025 *
246B
1.58B
Capitalization
131B
843M
Net income 2024
16.17B
104M
Net income 2025 *
11.66B
75.07M
EV / Sales 2024
0.63
x
Net Debt
2024
*
163B
1.05B
Net Debt
2025
*
162B
1.04B
EV / Sales 2025 *
1.19
x P/E ratio 2024
8.84
x
P/E ratio 2025 *
11.2
x
Employees
4,298
Yield 2024
2.07%
Yield 2025 *
2.27%
Free-Float
47.46%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Towa Pharmaceutical Completes Payment for Director Stock Compensation
Mar. 25
MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors
Mar. 06
CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-15
CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG).
22-03-06
CI
Towa Pharmaceutical Co., Ltd. agreed to acquire Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG) for ¥47.7 billion.
21-12-16
CI
Protosera, Inc. announced that it expects to receive funding from Towa Pharmaceutical Co., Ltd.
21-03-23
CI
Luye Pharma : Strikes Licensing Deal with Japan's Towa Pharma for Alzheimer's Disease Drug
21-02-18
MT
Luye Pharma Switzerland AG and Towa Pharmaceutical Co., Ltd. Enters Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan
21-02-17
CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Pensa Investments S.L. from Esteve Pharmaceuticals, S.A.
20-01-30
CI
Innophys Co., Ltd. announced that it has received ¥3.53 billion in funding from a group of investors
19-12-24
CI
Towa Pharmaceutical Co., Ltd. signed an agreement to acquire Pensa Investments S.L. from Esteve Pharmaceuticals, S.A.
19-12-22
CI
Innophys Co., Ltd. announced that it expects to receive funding from Hi-Lex Corporation
19-11-08
CI
Towa Pharmaceutical Co., Ltd. Announces Earnings Results for the Second Quarter of Fiscal Year 2016; Provides Earnings Guidance for the Full Year Ending March 2016; Revises Capital Expenditure Guidance for the Year Endings March 2017 and 2018
16-05-13
CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter Ended December 2015; Reaffirms Earnings Guidance for the Full Year Ending March 2016
16-02-07
CI
Certain common shares of Towa Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2016.
16-01-18
CI
More news
1 day -2.81%
1 week -1.84%
Current month -6.20%
1 month -4.38%
3 months -9.67%
6 months +5.89%
Current year +13.14%
More quotes
Managers
Title Age Since
President
73
79-04-30
Chief Administrative Officer
-
-
Director/Board Member
-
-
Members of the board
Title Age Since
President
73
79-04-30
Corporate Officer/Principal
70
81-08-31
Director/Board Member
76
15-05-31
More insiders
Date
Price
Change
Volume
24-05-16
2,661
-2.81%
146 200
24-05-15
2,738
-4.70%
445,700
24-05-14
2,873
+3.46%
314,700
24-05-13
2,777
0.00%
182,000
24-05-10
2,777
+1.61%
73,200
Delayed Quote
Japan Exchange, May 16, 2024 at 02:00 am EDT
More quotes
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
More about the company
Last Close Price
2,738
JPY
Average target price
3,690
JPY
Spread / Average Target
+34.77%
Consensus
1st Jan change
Capi.
+13.14% 870M +33.21% 709B +30.77% 595B -2.06% 367B +20.30% 334B +5.38% 289B +14.77% 239B +9.13% 211B -3.97% 203B +9.26% 171B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1